Director Christobel Selecky sells 159.5K shares of IBRX at $9.02 per share under pre-arranged 10b5-1 plan
Christobel Selecky, a director, sold 159,478 shares of ImmunityBio (IBRX) at $9.02 on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-13, generating $1,439,065.68 in proceeds. This transaction is scheduled rather than discretionary, eliminating timing as an interpretive factor. ImmunityBio reported a net income of $-632,782,000.00 in its most recent full fiscal year while generating quarterly revenue of $44,206,000.00, indicating significant near-term losses despite +668.3% annual revenue growth. The stock is currently trading at $8.91, approximately -28.3% from its 52-week high of $12.43 and 30-day return of +28.8%, reflecting recent upside recovery from depressed levels.